Bone fragility in midlife women remains chronically underdiagnosed, yet a single prior fracture is among the strongest predictors of future fractures — making early detection not just beneficial but potentially life-altering. As the global population ages, understanding the mechanistic link between menopause and accelerated bone loss has become one of primary care medicine's most pressing silent-disease challenges.
The central mechanism outlined in this clinical review centers on resorption-formation uncoupling: as estrogen levels fall during perimenopause and beyond, osteoclast activity outpaces osteoblast-driven bone rebuilding, progressively compromising skeletal microarchitecture. Diagnosis is standardized at a DXA T-score of ≤ −2.5, with plain radiography serving a complementary role when a fragility fracture is already evident — itself constituting diagnostic confirmation. The authors flag that DXA access is not universally Medicare-reimbursed in Australia, creating a structural barrier to detection in general practice settings where risk-based screening would otherwise be straightforward.
This review is largely confirmatory rather than paradigm-shifting, synthesizing established epidemiology and pathophysiology for a primary care audience. Yet its practical significance shouldn't be dismissed. Osteoporosis remains strikingly undermanaged: globally, fewer than 20% of women who sustain an osteoporotic fracture receive subsequent bone-density assessment or pharmacological treatment — the so-called "treatment gap" documented across multiple health systems. The prior-fracture risk signal highlighted here aligns with decades of longitudinal data, including FRAX tool development, reinforcing that fracture history should be a non-negotiable clinical trigger. The review's limitation is its educational rather than empirical orientation; it synthesizes rather than generates new evidence. For health-conscious adults, the key message embedded in this clinical framework is that bone density trajectories begin declining in the late 30s, and perimenopause dramatically accelerates that trajectory — meaning the detection window matters considerably.